Remove 2023 Remove Marketing Remove Safety
article thumbnail

A comment on the 2024 EWG Sunscreen Guide; Is EWG actively harming safe consumer sun protection?

The Eco Well Blog

Or are they putting these guides out as a fear marketing campaign to promote the EWG seal program (which makes them money)? 2023), when consumers had the option between “mineral” and “chemical” sunscreens, when blinded, overwhelmingly they preferred the “chemical” sunscreen. market while tests are still being conducted.

article thumbnail

NICE Recommends Lebrikizumab for Moderate to Severe AD in the NHS England

The Dermatology Digest

The treatment was approved by the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in December 2023. Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the United Kingdom and Switzerland in 2024.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD

The Dermatology Digest

In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis.

article thumbnail

Olive Oil vs Avocado Oil: What's the Difference?

Aesthetics Advisor

Olive Oil Market The global olive oil market is estimated to progress at a CAGR (Compound Annual Growth Rate) of 5.2% from 2023 to 2033. The market stands at a valuation of US 12 billion in 2023 and is expected to reach US 20 billion by 2033-end. Let's dive in. R ) What does extra virgin olive oil do?

article thumbnail

TDD Media Partner AARS Responds to the Valisure Citizen Petition on Benzene in Benzoyl Peroxide Drug Products

The Dermatology Digest

1,2 Benzene has become a more recent focus of attention related to safety concerns, with an increase in independent product testing and also updated regulations by the Food and Drug Administration related to benzene. Public safety is the first priority of the AARS. Right now, there are many questions about this issue. pp 9767-9777.

Rosacea 64
article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. The BIG story is Janus kinase ( JAK ) inhibitors,” Dr. Martin says.

article thumbnail

Biosimilar Watch: FDA Accepts BLA for Proposed Stelara Biosimilar 

The Dermatology Digest

The clinical results demonstrated that DMB-3115 and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of quality, safety and efficacy. In October of 2023, Accord BioPharma reached a settlement with Janssen Biotech Inc., market during the next five years.